Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Beta-lactams against methicillin-resistant Staphylococcus aureus.

Bertrand Guignard¹, José M Entenza, Philippe Moreillon

¹University of Lausanne, Department of Fundamental Microbiology, Biology Building, 1015 Lausanne, Switzerland.

Current Opinion in Pharmacology

|August 13, 2005

Summary

Newer beta-lactam antibiotics targeting penicillin-binding protein 2A (PBP2A) show promise for treating methicillin-resistant Staphylococcus aureus (MRSA) infections. These advanced drugs are nearing clinical availability, offering hope against resistant bacterial strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Community pharmacists' practices and clinical reasoning towards hospital discharge prescription: a study using simulations and retrospective think-aloud methodology.

International journal of clinical pharmacy·2025

Same author

A graphical model to make explicit pharmacist clinical reasoning during medication review.

Research in social & administrative pharmacy : RSAP·2024

Same author

External Validation of the 2023 Duke-International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024

Same author

Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis.

International journal of clinical pharmacy·2024

Same author

Development and retrospective evaluation of a clinical decision support system for the efficient detection of drug-related problems by clinical pharmacists.

International journal of clinical pharmacy·2022

Same author

Patients' perceptions of conflicting information on chronic medications: a prospective survey in Switzerland.

BMJ open·2022

Area of Science:

Microbiology
Pharmacology
Infectious Diseases

Background:

Methicillin-resistant Staphylococcus aureus (MRSA) exhibits resistance to most antibiotics, including beta-lactams, due to the PBP2A enzyme.
Penicillin-binding protein 2A (PBP2A) allows MRSA to synthesize its cell wall even when other penicillin-binding proteins are inhibited.

Purpose of the Study:

To investigate the development of novel beta-lactam antibiotics effective against MRSA by targeting PBP2A.
To assess the efficacy of these new agents in preclinical and clinical settings.

Main Methods:

Development of novel beta-lactam antibiotics with high affinity for PBP2A.
Evaluation of these compounds against MRSA in animal infection models.
Clinical trials (Phase II and III) for promising candidates like CS-023 and ceftopibrole medocaril.

Related Experiment Videos

Main Results:

Newer beta-lactams demonstrate significantly higher PBP2A affinities and lower minimal inhibitory concentrations.
These agents show efficacy in animal models of MRSA infection.
Two compounds, CS-023 and ceftopibrole medocaril, have advanced to later stages of clinical evaluation.

Conclusions:

Targeting PBP2A is a viable strategy for developing effective anti-MRSA beta-lactams.
Clinically useful antibiotics for treating MRSA infections are anticipated soon.
These advancements offer potential solutions for combating antibiotic resistance.